![]() | |
![]() | |
Clinical data | |
---|---|
Trade names | Xarelto, others |
Other names | BAY 59-7939 |
AHFS/ Drugs.com | Monograph |
MedlinePlus | a611049 |
License data |
|
Pregnancy category |
|
Routes of administration | By mouth |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Bioavailability | 80–100%; Cmax = 2–4 hours (10 mg oral) [1] |
Metabolism | CYP3A4, CYP2J2 and CYP-independent mechanisms [1] |
Elimination half-life | 5–9 hours in healthy subjects aged 20 to 45 [1] [2] |
Excretion | 2/3 metabolized in liver and 1/3 eliminated unchanged [1] |
Identifiers | |
| |
Chemical and physical data | |
Formula | C19H18ClN3O5S |
Molar mass | 435.88 g·mol−1 |
3D model ( JSmol) | |
| |
| |
![]() ![]() |
Rivaroxaban, sold under the brand name Xarelto among others, is an anticoagulant medication (blood thinner) used to treat and prevent blood clots. [4] Specifically it is used to treat deep vein thrombosis and pulmonary emboli and prevent blood clots in atrial fibrillation and following hip or knee surgery. [4] It is taken by mouth. [4]
Common side effects include bleeding. [4] Other serious side effects may include spinal hematoma and anaphylaxis. [4] It is unclear if use in pregnancy and breastfeeding is safe. [5] Compared to warfarin it has fewer interactions with other medications. [6] It works by blocking the activity of the clotting protein factor Xa. [4]
Rivaroxaban was patented in 2007 and approved for medical use in the United States in 2011. [7] It is on the World Health Organization's List of Essential Medicines as an alternative to dabigatran. [8] In the United States, it will not be available as a generic medication until 2024. [9] [10] A month supply in the United Kingdom costs the NHS about £50 as of 2020. [11] In the United States, the wholesale cost of this amount is about US$430. [12] In 2017, it was the 109th most commonly prescribed medication in the United States, with more than six million prescriptions. [13] [14]
{{
cite book}}
: CS1 maint: date format (
link)
![]() | |
![]() | |
Clinical data | |
---|---|
Trade names | Xarelto, others |
Other names | BAY 59-7939 |
AHFS/ Drugs.com | Monograph |
MedlinePlus | a611049 |
License data |
|
Pregnancy category |
|
Routes of administration | By mouth |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Bioavailability | 80–100%; Cmax = 2–4 hours (10 mg oral) [1] |
Metabolism | CYP3A4, CYP2J2 and CYP-independent mechanisms [1] |
Elimination half-life | 5–9 hours in healthy subjects aged 20 to 45 [1] [2] |
Excretion | 2/3 metabolized in liver and 1/3 eliminated unchanged [1] |
Identifiers | |
| |
Chemical and physical data | |
Formula | C19H18ClN3O5S |
Molar mass | 435.88 g·mol−1 |
3D model ( JSmol) | |
| |
| |
![]() ![]() |
Rivaroxaban, sold under the brand name Xarelto among others, is an anticoagulant medication (blood thinner) used to treat and prevent blood clots. [4] Specifically it is used to treat deep vein thrombosis and pulmonary emboli and prevent blood clots in atrial fibrillation and following hip or knee surgery. [4] It is taken by mouth. [4]
Common side effects include bleeding. [4] Other serious side effects may include spinal hematoma and anaphylaxis. [4] It is unclear if use in pregnancy and breastfeeding is safe. [5] Compared to warfarin it has fewer interactions with other medications. [6] It works by blocking the activity of the clotting protein factor Xa. [4]
Rivaroxaban was patented in 2007 and approved for medical use in the United States in 2011. [7] It is on the World Health Organization's List of Essential Medicines as an alternative to dabigatran. [8] In the United States, it will not be available as a generic medication until 2024. [9] [10] A month supply in the United Kingdom costs the NHS about £50 as of 2020. [11] In the United States, the wholesale cost of this amount is about US$430. [12] In 2017, it was the 109th most commonly prescribed medication in the United States, with more than six million prescriptions. [13] [14]
{{
cite book}}
: CS1 maint: date format (
link)